Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Galapagos NV ADR (NQ: GLPG )

25.38 +0.04 (+0.16%)
Streaming Delayed Price Updated: 10:04 AM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Galapagos NV ADR

< Previous 1 2 3 4 Next >
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
BofA Securities downgrades Galapagos to underperform due to limited near-term catalysts and competitive challenges in crowded markets. 
Via Benzinga
European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG). 
Via Benzinga
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023. 
Via InvestorPlace
8 Analysts Have This to Say About Galapagos
Via Benzinga
Where Galapagos Stands With Analysts
Via Benzinga
JP Morgan Maintains Neutral Rating for Galapagos: Here's What You Need To Know
Via Benzinga
Earnings Outlook For Galapagos
Via Benzinga
Earnings Preview For Galapagos
Via Benzinga
Where Galapagos Stands With Analysts
Galapagos (NASDAQ:GLPG) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Where Galapagos Stands With Analysts
Analysts have provided the following ratings for Galapagos (NASDAQ:GLPG) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 8, 2023
Via Benzinga
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Galapagos' Blood Cancer Candidate Shows 100% Objective Response Rate In Relapsed/Refractory Patients
Via Benzinga
Galapagos Bets €225M On CellPoint Marking Its Entry Into CAR-T Field
Via Benzinga
Galapagos In-licenses Inflammatory Bowel Disease Drug Targets From Scipher Medicine
Via Benzinga
Why Galapagos Stock Is Falling Today
Galapagos NV (NASDAQ: GLPG) announced the topline results from the DIVERSITY Phase 3 trial of filgotinib during induction and maintenance treatment of biologic-naïve and biologic-experienced patients... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 23, 2023
Via Benzinga
Twitter Rolls Out 'Blue For Business,' Visa Pitches Auto-Payments On Ethereum Blockchain, Justin Bieber Slams H&M: Today's Top Stories
Benzinga 
Via Benzinga
On A Mission As Top European Player, Galapagos Looks For Acquisition Targets
Galapagos NV (NASDAQ: GLPG) is reportedly looking for M&A deals with companies with products still in the preclinical or early stage of development. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 7, 2022
Upgrades 
Via Benzinga
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
Via Benzinga
Expert Ratings for Galapagos
Over the past 3 months, 4 analysts have published their opinion on Galapagos (NASDAQ:GLPG) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
3 Biotech Stocks to Sell in October
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
Via InvestorPlace
Lyft, DoorDash, Expedia And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Atlas Corp. (NYSE: ATCO) rose 21.4% to $14.06 in pre-market trading after the company said it received a non-binding proposal from Poseidon Acquisition Corp. to acquire all outstanding common shares of... 
Via Benzinga
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet. 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.